Method to produce induced Pluripotent Stem (iPS) Cells from non-embryonic human
Inventors: George Daley, In-Hyun Park, Suneet Agarwal, Paul Lerou
Invention Types: Therapeutics
Research Areas: Personalized Medicine, Regenerative Medicine, Stem Cell
Keywords: Disease Model, Stem/Progenitor Cell, Tissue Engineering, Gene TherapyFor More Information Contact: Meyer, Abbie
Using ectopic expression of transcription factors including Oct4, Sox2, Klf4 and Myc and other factors in human fibroblasts and mesenchymal cells, the Daley group has created induced pluripotent stem (iPS) cells from fetal, neonatal and adult primary cells. These iPS cells, which can be made using a single polycistronic vector, resemble embryonic stem cells in morphology and gene expression and in their pluripotent capacity.
In addition to healthy iPS cells, Daley has made iPS from individuals with genetic diseases including ADA-SCID, Gaucher's Disease, Huntington's Disease, Type 1 Diabetes Mellitus, Duchenne and Becker's Muscular Dystrophy, Down Syndrome and others.
Platform technology: Generation of patient- and disease-specific models for drug discover and Cell lines many lines are available for internal research use.
Pluripotent cells that avoid use of ESCs, Creation of iPS from individuals with genetic mutations, Study of known genotype on phenotype, Model of human diseases, access to cells along the development pathway.
License of IP and normal and disease-specific iPS lines for drug screening.
Key Publications: Reprogramming of human somatic cells to pluripotency with defined factors
In-Hyun Park1, Rui Zhao1, Jason A. West, Akiko Yabuuchi, Hongguang Huo, Tan A. Ince, Paul H. Lerou,
M. William Lensch & George Q. Daley
Related Publications: Cell. 2008 Sep 5;134(5):877-86.
Nat Protoc. 2008;3(7):1180-6.
Nature. 2008 Jan 10;451(7175):141-6.
IPStatus: Pat. Pend.